{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T14:05:30Z","timestamp":1790863530432,"version":"4.1.0"},"reference-count":0,"publisher":"Oxford University Press (OUP)","license":[{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"am","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Late-line treatment options for microsatellite stable (MSS)\/proficient mismatch repair (pMMR) metastatic colorectal cancer (mCRC) are limited. PD-1 blockade alone has minimal clinical benefit in this population. Human epidermal growth factor receptor 2 (HER2)-targeted therapies represent an emerging strategy for HER2-expressing mCRC. This study evaluated the efficacy and safety of pembrolizumab combined with disitamab vedotin (DV), an anti-HER2 antibody-drug conjugate (ADC), in pretreated patients with HER2-positive mCRC.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>This multicenter, single-arm, phase II study enrolled patients with MSS\/pMMR, HER2-positive mCRC who received 2 prior lines of systemic therapy. Patients received pembrolizumab 400\u2009mg every 6 weeks plus DV 2.5\u2009mg\/kg every 2 weeks until disease progression, unacceptable toxicity, or death. Primary endpoint was objective response rate (ORR). Secondary endpoints included progression-free survival (PFS), overall survival (OS), and safety.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Between December 2022 and May 2024, 15 patients (median age 59.0 years; 60.0% male) were enrolled. Fourteen patients (93.3%) had HER2 IHC 3+ expressions, and two had received prior anti-HER2 therapy. Two patients achieved partial response, (ORR=13.3%; 95% CI, 1.7%-40.5%). With median follow-up of 26.7 months, median PFS was 2.9 months (95% CI, 2.3 to not reached). Median OS was not reached (95% CI, 16.7 to NR). The 6-month OS rate of 92.9% (95% CI: 6.9%-80.3%) and the 1-year OS rate was 71.4% (95% CI: 51.3%-99.5%). The most common treatment-related adverse events (TRAEs) included nausea, anorexia, alanine aminotransferase elevation, aspartate aminotransferase elevation, and alopecia. Grade 3-4 TRAEs occurred in two patients (14.3%), both neutropenia.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Pembrolizumab plus disitamab vedotin showed limited antitumor activity in pretreated HER2-positive mCRC.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>ClinicalTrials.gov Identifier<\/jats:title>\n                    <jats:p>NCT05333809<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/oncolo\/oyag385","type":"journal-article","created":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T11:58:36Z","timestamp":1790769516000},"source":"Crossref","is-referenced-by-count":0,"title":["Pembrolizumab Combined with Disitamab Vedotin in Human Epidermal Growth Factor Receptor 2-Positive Metastatic Colorectal Cancer"],"prefix":"10.1093","author":[{"given":"Xiaojing","family":"Xu","sequence":"first","affiliation":[{"name":"Fudan University Department of Oncology, Zhongshan Hospital, , Shanghai,","place":["China"]},{"name":"Fudan University Cancer Center, Zhongshan Hospital, , Shanghai,","place":["China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Minzhi","family":"Lv","sequence":"additional","affiliation":[{"name":"Fudan University Department of Cancer Screening and Prevention, Zhongshan Hospital, , Shanghai,","place":["China"]},{"name":"Fudan University Evidence-based medicine Center, , Shanghai,","place":["China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luoyan","family":"Ai","sequence":"additional","affiliation":[{"name":"Fudan University Department of Oncology, Zhongshan Hospital, , Shanghai,","place":["China"]},{"name":"Fudan University Cancer Center, Zhongshan Hospital, , Shanghai,","place":["China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qing","family":"Wang","sequence":"additional","affiliation":[{"name":"Fudan University Department of Oncology, Zhongshan Hospital, , Shanghai,","place":["China"]},{"name":"Fudan University Cancer Center, Zhongshan Hospital, , Shanghai,","place":["China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuehong","family":"Cui","sequence":"additional","affiliation":[{"name":"Fudan University Department of Oncology, Zhongshan Hospital, , Shanghai,","place":["China"]},{"name":"Fudan University Cancer Center, Zhongshan Hospital, , Shanghai,","place":["China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei","family":"Li","sequence":"additional","affiliation":[{"name":"Fudan University Department of Oncology, Zhongshan Hospital, , Shanghai,","place":["China"]},{"name":"Fudan University Cancer Center, Zhongshan Hospital, , Shanghai,","place":["China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qing","family":"Liu","sequence":"additional","affiliation":[{"name":"Fudan University Department of Oncology, Zhongshan Hospital, , Shanghai,","place":["China"]},{"name":"Fudan University Cancer Center, Zhongshan Hospital, , Shanghai,","place":["China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xi","family":"Tang","sequence":"additional","affiliation":[{"name":"Fudan University Department of Oncology, Huadong Hospital, , Shanghai,","place":["China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xi","family":"Chen","sequence":"additional","affiliation":[{"name":"Fudan University Department of Oncology, Huadong Hospital, , Shanghai,","place":["China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shan","family":"Yu","sequence":"additional","affiliation":[{"name":"Fudan University Department of Oncology, Zhongshan Hospital, , Shanghai,","place":["China"]},{"name":"Fudan University Cancer Center, Zhongshan Hospital, , Shanghai,","place":["China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mengzhou","family":"Guo","sequence":"additional","affiliation":[{"name":"Fudan University Department of Oncology, Zhongshan Hospital, , Shanghai,","place":["China"]},{"name":"Fudan University Cancer Center, Zhongshan Hospital, , Shanghai,","place":["China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yiyi","family":"Yu","sequence":"additional","affiliation":[{"name":"Fudan University Department of Oncology, Zhongshan Hospital, , Shanghai,","place":["China"]},{"name":"Fudan University Cancer Center, Zhongshan Hospital, , Shanghai,","place":["China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tianshu","family":"Liu","sequence":"additional","affiliation":[{"name":"Fudan University Department of Oncology, Zhongshan Hospital, , Shanghai,","place":["China"]},{"name":"Fudan University Cancer Center, Zhongshan Hospital, , Shanghai,","place":["China"]},{"name":"Fudan University Evidence-based medicine Center, , Shanghai,","place":["China"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2026,10,1]]},"container-title":["The Oncologist"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/oncolo\/advance-article-pdf\/doi\/10.1093\/oncolo\/oyag385\/71560033\/oyag385.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/oncolo\/advance-article-pdf\/doi\/10.1093\/oncolo\/oyag385\/71560033\/oyag385.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T13:38:38Z","timestamp":1790861918000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/oncolo\/advance-article\/doi\/10.1093\/oncolo\/oyag385\/8859121"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10,1]]},"references-count":0,"URL":"https:\/\/doi.org\/10.1093\/oncolo\/oyag385","relation":{},"ISSN":["1083-7159","1549-490X"],"issn-type":[{"value":"1083-7159","type":"print"},{"value":"1549-490X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,10,1]]},"article-number":"oyag385"}}